Sign in
Not yet recruitingPhase 1

A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated Triglycerides

Key facts

Who runs it
Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
25 Aug 2026
Expected to end
20 Dec 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Intervention1: FXR0906 injection
  • Intervention2: FXR0906 injection
  • Placebo
Record updated
14 August 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Males or females aged ≥18 and ≤55 years at the time of screening; 2. Body mass index (BMI) ≥18.0 and ≤35.0 kg/m² at the time of screening, with female participants weighing >45 kg and male participants weighing >50 kg; 3. Fasting serum triglyceride (TG) level TG > 80 mg/dL (0.90 mmol/L) during screening; 4. Fasting LDL-C level ≥ 70 mg/dL (1.81 mmol/L) during screening; Exclusion criteria: 1. History or presence of clinically significant diseases/abnormality, or with clinically significant symptoms/signs, or self-reported diseases, unsuitable for enrollement in the judgement of the investigator
  • Fasting blood glucose ≥7.0 mmol/L or HbA1c ≥6.5% during screening. 3. Use of any lipid-lowering treatment (e.g., drugs lowering LDL-C or TG), including but not limited to statins, ezetimibe, fibrates, omega-3 fatty acids, nutritional supplements, or other treatment regimens altering serum lipids within 30 days prior to screening, or use of any ASO or siRNA therapies lowering serum lipids within 12 months prior to screening
  • Use of investigational drugs or instruments within 3 months prior to screening , or plans to participate in other clinical trials during this study. 5. Clinical laboratory parameters during screening meeting any of the following criteria:
  • ALT and/or AST >1.5 × ULN
  • ALT and/or AST > ULN and ≤1.5 × ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
  • INR > ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
  • Estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2 (using MDRD formula)
  • Other examination abnormalities deemed clinically significant and unsuitable for participation in the clinical trial by the investigator

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of FXR0906 injection or placebo in Chinese healthy adult volunteers with or without TG increase.

The 3 groups in the trial

  • Arm1: FXR0906 injectionTreatment being tested

    Dose 1 of FXR0906 injection

    Treatment: Intervention1: FXR0906 injection

  • Arm2: FXR0906 injectionTreatment being tested

    dose 2 of FXR0906 injection

    Treatment: Intervention2: FXR0906 injection

  • Arm3: placebo comparator: placeboPlacebo, for comparison

    placebo

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FXR0906 in Healthy Adult Participants With or Without Elevated Triglycerides
Criteria questions
Built from NCT07766759, who can take part
Record updated
14 August 2026